1217 ECP Vigil
BioCentury & Getty Images

Emerging Company Profile

Vigil: restoring the vigilance of microglia

Emerging Company Profile: After debuting with $50M, Atlas’ Vigil plans to pursue rare microgliopathies with assets from Amgen

The Atlas incubated biotech will use its $50 million series A to advance in-licensed assets from Amgen in rare genetic disorders that affect the brain’s white matter.

Dec 17, 2020 | 2:44 PM GMT

Incubated by Atlas Venture

Read the full 675 word article

How to gain access

Continue reading with a
two-week free trial.